Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced a new initiative in collaboration with the National Foundation of Ectodermal Dysplasias (NFED) -- the Ectodermal Dysplasias Regional Conferences. This series of regional conferences is being planned in collaboration with hospitals and academic centers around the United States and will provide healthcare providers and families an opportunity to come together to discuss ectodermal dysplasias.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
